Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05593640

Thromboxane A2 and Osteoarthritis

Conditions: Osteoarthritis

Sex: All
Ages: 40 Years – N/A
Healthy volunteers: No
Enrollment: 20
Sponsor: Centre Hospitalier Universitaire de Nice

Location: CHU de NICE Nice

Summary

TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i) to analyse the role of TXA2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue TXA2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of TXA2 with the development of osteoarthritis in a small human cohort. The proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat OA and associated metabolic disorders.

Eligibility Criteria

Inclusion Criteria: * presence of knee osteoarthritis with effusion, , no inflammatory disease Exclusion Criteria: * anticoagulant treatment * inflammatory disease

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05593640). StuddyBuddy aggregates publicly available trial information.